论文部分内容阅读
继左旋多巴及其脱羧酶抑制剂联合应用之后，多巴胺能激动剂的研究与应用受到重视。应用麦角类多巴胺能激动剂不但减少了左旋多巴的用量，并能进一步改善患者症状。但随着应用时间延长，对这类激动剂的反应发生退化，出现某些与麦角结构相关的不良反应。近年来开发出非麦角类新
Following the combined use of levodopa and its decarboxylase inhibitors, the research and application of dopaminergic agonists are valued. Application of ergot class dopaminergic agonist not only reduces the amount of levodopa, and can further improve the patient’s symptoms. However, as the application time prolonged, the response to such agonists degenerated and some of the ergot-related adverse reactions occurred. In recent years developed a non-ergot class new